Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 612-396-8 | CAS number: 61791-19-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- From 02 June 1992 to 24 September 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment; compliant with GLP.
- Justification for data waiving:
- other:
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- secondary source
- Title:
- Unnamed
- Year:
- 1 999
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- A 13-week toxicity study in F344/N rats was conducted by NTP to evaluate the cumulative toxic effects of repeated dermal exposure to the test substance.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- N,N-bis(2-hydroxyethyl)oleamide
- EC Number:
- 202-281-7
- EC Name:
- N,N-bis(2-hydroxyethyl)oleamide
- Cas Number:
- 93-83-4
- IUPAC Name:
- N,N-bis(2-hydroxyethyl)octadec-9-enamide
- Reference substance name:
- Oleic acid diethanolamine condensate
- IUPAC Name:
- Oleic acid diethanolamine condensate
- Details on test material:
- - Name of test material (as cited in study report): Oleic acid diethanolamine condensate
- Source of the test material: Obtained from Henkel Corporation, Emery Group (Cincinnati, OH)
- Molecular weight: 387.68
- Physical state: Clear liquid
- Analytical purity: Purity of 47.5% was obtained when analyzed by HPLC
- Impurities (identity and concentrations): Analyzed by HPLC/mass spectrometry. Impurities identified were fatty acid alkanolamides (approximately 30%), other fatty acids or unidentified organic impurities, one polar nitrosamines (i.e., nitrosodiethanolamine was detected at a concentration of 68 ppb), free diethanolamine at 0.19%; no non-polar nitrosamine were found.
- Lot/batch No.: 1H01722285 (for purity determination by HPLC method) and DA-021 (for stability studies by gas chromatography)
- Stability under test conditions: Stable when stored in glass vials for 2 wk at 25 °C but unstable at 60 °C.
- Storage condition of test material: At room temperature, protected from ultraviolet light, in amber glass bottles with Teflon®-lined lids
- Other: Solubility: soluble in alcohols, glycols, ketones, chlorinated solvents, and other aliphatic hydrocarbon solvents.
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: Taconic Farms (Germantown, NY)
- Age at study initiation: 8 wk
- Housing: Housed individually in polycarbonate cages
-Method of distribution: Animals were distributed randomly into groups of approximately equal initial mean body weights.
- Bedding: Sani-Chip® heat-treated hardwood chips (P.J. Murphy Forest Products Corp., Montville, NJ), changed weekly
- Diet: NIH-07 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), available ad libitum
- Water: Tap water (Columbus municipal supply) via automatic watering system (Edstrom Industries, Inc., Waterford, WI), available ad libitum
- Acclimation period: Males: 23 d and Females: 24 d
- Cages: Polycarbonate (Lab Products, Inc., Maywood, NJ), changed weekly and rotated every 2 wks
- Animal number per cage: 1
- Cage Filters: Spun-bonded polyester Du Pont 2024 (Snow Filtration, Co., Cincinnati, OH), changed every 2 wks
- Racks: Stainless steel drawer-type (Lab Products, Inc., Maywood, NJ), changed and rotated every 2 wks
ENVIRONMENTAL CONDITIONS
- Temperature: 21.1-22.8°C
- Relative humidity: 37-65 %
- Air changes: 10/h
- Photoperiod: 12 h dark/12 h light
IN-LIFE DATES: From: 1992-06-02 To: 1992-09-24 (males); 1992-06-02 To: 1992-09-25 (females)
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- ethanol
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The dose formulations were prepared every 3 weeks by mixing (i.e., by stirring or sonicating) the test substance with 95% ethanol to give the required concentrations. The test substance formulations were applied on shaved interscapular skin of the test animals.
- Storage of dose formulations: The dose formulations were stored at room temperature, protected from light, in amber glass bottles for up to 28 days.
- Stability studies of a 10 mg/mL formulation prepared from lot CH1F980 (not used) were performed by the study laboratory using high-performance liquid chromatography. Stability of the dose formulation was confirmed for at least 28 days when stored in sealed containers, protected from ultraviolet light, at up to room temperature or for 3 hours when stored open to air and light. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Periodic analyses of the dose formulations of the test substance from the beginning, middle, and end of the study were analyzed using HPLC. All the samples from the formulations analyzed during the 13 week study were within 10% of the target concentration.
- Stability of dose formulations: Stability was confirmed for at least 28 days when stored in sealed containers, protected from ultraviolet light, at up to room temperature or for 3 hours when stored open to air and light. - Duration of treatment / exposure:
- 13 wks
- Frequency of treatment:
- 5 exposures/wk
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 25, 50, 100, 200, or 400 mg/kg bw/day (0, 30, 61, 121, 243, or 485 mg/mL in ethanol)
Basis:
nominal per unit body weight
- No. of animals per sex per dose:
- 10/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Method of animal grouping: Distributed randomly into groups of approximately equal initial mean body weights.
- Positive control:
- Not used in the study
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical findings were recorded weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Weighed initially, weekly, and again at the end of the study
HAEMATOLOGY: Yes
- Time schedule for collection of blood: On Days 5 and 19 and all core study rats surviving to the end of the study
- Method: Blood was collected from the retro-orbital sinus of special study rats from each dose group
- Anaesthetic used for blood collection: Yes, carbon dioxide/oxygen mixture
- How many animals: All animals
- Parameters examined.: Hematocrit; hematocrit; hemoglobin; erythrocyte, nucleated erythrocyte, reticulocyte, and platelet counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; leukocyte counts and differentials
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: On Days 5 and 19 (blood was collected from the retro-orbital sinus of special study rats from each dose group) and all core study rats surviving to the end of the study.
- How many animals: All animals
- Parameters examined: Urea nitrogen, creatinine, alanine aminotransferase, alkaline phosphatase, sorbitol dehydrogenase, total protein, albumin, and bile salts
OTHER: Organs weight: Organ weights were determined for heart, right kidney, liver, lung, right testis, and thymus - Sacrifice and pathology:
- SACRIFICE: At the end of the 13-week study animals were sacrificed by carbon dioxide asphyxiation.
GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes.
- Complete histopathology was performed on 0 and 400 mg/kg bw/day study rats. In addition to gross lesions and tissue masses, the tissues examined were: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular), testis (and epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, and uterus. In addition, the skin was examined in all rats.
- All major tissues were fixed and preserved in 10% neutral buffered formalin processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6 μm, and stained with hematoxylin and eosin for microscopic examination. - Other examinations:
- Sperm Motility and Vaginal Cytology:
- Samples were collected for sperm motility or vaginal cytology from all rats in the 0, 100, 200, and 400 mg/kg bw/day groups.
- The sperm motility parameters evaluated was: Sperm concentration, sperm motility, sperm count, spermatid heads per testis, and spermatid heads per gram of testis. The left cauda, epididymis, and testis were weighed.
- Vaginal samples were collected for 12 consecutive days prior to the end of the studies for vaginal cytology evaluations.
- The parameters observed were: Estrous cycle length and relative frequency of estrous stage. - Statistics:
- Statistical analyses for possible dose-related effects on survival used Cox’s (1972) method for testing two groups for equality and Tarone’s (1975) life table test to identify dose-related trends.
- Analysis of neoplasm and non-neoplastic lesion incidences: The Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence. Tests of significance included pair wise comparisons of each dosed group with controls and a test for an overall dose-related trend. Continuity-corrected tests were used in the analysis of lesion incidence, and reported P values are one sided. Values of P greater than 0.5 are presented as 1-P with the letter N added to indicate a lower incidence or negative trend in neoplasm occurrence relative to the control group (e.g., P=0.99 is presented as P=0.01N).
- Analysis of Continuous Variables: Organ and body weight data were analysed using the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). Hematology, clinical chemistry, spermatid, and epididymal spermatozoal data were analysed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey. Average severity values were analyzed for significance with the Mann-Whitney U test (Hollander and Wolfe, 1973). Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976) to the transformed data to test for simultaneous equality of measurements across dose levels.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- (all animals survived to the end of the study)
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- (irritation of the skin at the site of application in males administered 100 mg/kg bw/day or greater and in females administered 50 mg/kg bw/day or greater)
- Mortality:
- no mortality observed
- Description (incidence):
- (all animals survived to the end of the study)
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- (reduced final mean body weights and body weight gains of males and/or females at 200 or 400 mg/kg bw/day)
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- (increased segmented neutrophil counts in the 400 mg/kg bw/day male group on Day 5 and 19, in the 200 mg/kg bw/day female group on Day 19 and at wk 13 and in the 400 mg/kg bw/day female group on Day 5 and 19 and at wk 13).
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- (significant increase in alkaline phosphatase activity on Day 19 in males at 200 mg/kg bw/day, at wk 13 in females at 200 mg/kg bw/day and at wk 13 in males and females at 400 mg/kg bw/day)
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- (Increased kidney weights in females at 200 and 400 mg/kg bw/day; decreased heart, liver, lung and thymus weights in males and females in the 200 and 400 mg/kg bw/day groups were associated with the lower mean body weights of these groups)
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- (dose dependent increase in the incidences of non-neoplastic lesions of the skin (including hyperplasia of the epidermis, hypertrophy of sebaceous gland, parakeratosis, chronic active inflammation of the dermis and suppurative epidermal inflammation); In
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- None
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- (local effects)
- Effect level:
- 25 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- NOAEL
- Remarks:
- (systemic effects)
- Effect level:
- 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: overall effects (i.e., decreased body weight and body weight gain, increased segmented neutrophil counts, increased alkaline phosphatase concentrations, increased kidney weights in males and/or females at ≥200 mg/kg bw/day)
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
- Non-neoplastic lesions: Lesions of the skin were also present at the site of application in groups administered 100 mg/kg bw/day; however, the incidences were somewhat less than those observed in the 200 and 400 mg/kg bw/day groups. In addition, the severities of the lesions were increased only slightly in the 200 and 400 mg/kg bw/day groups compared to the severities in the 100 mg/kg bw/day groups. Moreover, it was considered unlikely that these lesions would progress and become life threatening over the period of a 2 -year study. In groups treated with 50 mg/kg bw/day, the incidences of skin lesions diminished considerably and lesion severities were minimal.
- Other observed parameters (sperm and vaginal): There were no significant differences in sperm motility and vaginal cytology parameters between dosed and vehicle control groups.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the 13-week study in rats, the NOAEL for systemic and local effects can be considered to be at 100 and 25 mg/kg bw/day respectively.
- Executive summary:
A study was conducted by NTP to evaluate the cumulative toxic effects following repeated dermal exposure to oleic acid diethanolamine condensate (ODEA) in F344/N rats.
Groups of 10 male and 10 female rats were dermally exposed to 0, 25, 50, 100, 200, or 400 mg test substance/kg bw/day in ethanol at a frequency of 5 d/wk for a period of 13 weeks. Survival, clinical findings, body weight, hematology, clinical chemistry and histopathology were evaluated at specific time intervals.
All animals survived until study termination. The final mean body weights and body weight gains of 200 and 400 mg/kg bw/day males and the mean body weight gain of 400 mg/kg bw/day females were significantly less than those of the vehicle controls. The only chemical-related clinical finding was irritation of the skin at the site of application in most males administered 100 mg/kg bw/day or greater and in all females administered 50 mg/kg bw/day or greater. Segmented neutrophil counts and alkaline phosphatase concentrations were increased significantly on specific days in the 200 and/or 400 mg/kg bw/day male and female groups. Kidney weights of 200 and 400 mg/kg females were significantly greater than those of the vehicle controls. There was a dose dependent increase in the incidence of non-neoplastic lesions of the skin at the site of application, including epidermal hyperplasia, parakeratosis, chronic active dermal inflammation, suppurative epidermal inflammation, and sebaceous gland hypertrophy in dosed rats. However, these effects were minimal in the 50 mg/kg bw/day dose group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.